Phase 3 #SymptomScience @nejm.org RCT of elinzanetant vs placebo for moderate-to-severe vasomotor symptoms in HR+ #breast cancer (n=474) @ascocancer.bsky.social @cancercaremascc.bsky.social @hoperugo.bsky.social @coffeemommy.bsky.social @stage4kelly.bsky.social www.nejm.org/doi/full/10....
September 1, 2025 at 6:50 PM
Phase 3 #SymptomScience @nejm.org RCT of elinzanetant vs placebo for moderate-to-severe vasomotor symptoms in HR+ #breast cancer (n=474) @ascocancer.bsky.social @cancercaremascc.bsky.social @hoperugo.bsky.social @coffeemommy.bsky.social @stage4kelly.bsky.social www.nejm.org/doi/full/10....
#SymptomScience pilot study showing feasibility of low-intensity vibration to reduce #CIPN and improve physical function in cancer survivors @advocatecollab.bsky.social @ascocancer.bsky.social @cancercaremascc.bsky.social @pallonccop.bsky.social @ryannipp.bsky.social ascopubs.org/doi/10.1200/...
May 16, 2025 at 12:02 AM
#SymptomScience pilot study showing feasibility of low-intensity vibration to reduce #CIPN and improve physical function in cancer survivors @advocatecollab.bsky.social @ascocancer.bsky.social @cancercaremascc.bsky.social @pallonccop.bsky.social @ryannipp.bsky.social ascopubs.org/doi/10.1200/...
Here is a great @ascocancer.bsky.social JCO #ASCOGuidelines resource ascopubs.org/doi/10.1200/... #SymptomScience
Management of Fatigue in Adult Survivors of Cancer: ASCO–Society for Integrative Oncology Guideline Update
ASCO–Society for Integrative Oncology (SIO) Guidelines provide recommendations with
comprehensive review and analyses of the relevant literature for each recommendation,
following the guideline develo...
ascopubs.org
May 13, 2025 at 2:41 AM
Here is a great @ascocancer.bsky.social JCO #ASCOGuidelines resource ascopubs.org/doi/10.1200/... #SymptomScience
Thankful @nejm.org #CancerCachexia ponsegromab study highlighted as NEJM Notable Articles of 2024 #SymptomScience www.nejm.org/doi/full/10.... @ascocancer.bsky.social @cancercachexia.bsky.social @pallonccop.bsky.social @cancercaremascc.bsky.social @ohsuknight.bsky.social @drr-dunne.bsky.social
December 19, 2024 at 2:06 PM
Thankful @nejm.org #CancerCachexia ponsegromab study highlighted as NEJM Notable Articles of 2024 #SymptomScience www.nejm.org/doi/full/10.... @ascocancer.bsky.social @cancercachexia.bsky.social @pallonccop.bsky.social @cancercaremascc.bsky.social @ohsuknight.bsky.social @drr-dunne.bsky.social
@jama.com #scanxiety RCT of CBD v placebo in women with #breastcancer (n=50) led by @ascocancer.bsky.social Cannabis #ASCOGuidelines Co-Chair, Dr. Ilana Braun. No difference primary end point (VAMS afraid subscale). More work to be done #PallOnc #SymptomScience jamanetwork.com/journals/jam...
Cannabidiol for Scan-Related Anxiety in Women With Advanced Breast Cancer
This randomized clinical trial investigates whether a single oral dose of cannabidiol improves scan-related anxiety in women with advanced breast cancer.
jamanetwork.com
December 19, 2024 at 12:36 PM
@jama.com #scanxiety RCT of CBD v placebo in women with #breastcancer (n=50) led by @ascocancer.bsky.social Cannabis #ASCOGuidelines Co-Chair, Dr. Ilana Braun. No difference primary end point (VAMS afraid subscale). More work to be done #PallOnc #SymptomScience jamanetwork.com/journals/jam...
@sarahlowry.bsky.social Welcome my friend. Glad to see you here. Where are all our incredible APP colleagues? #PallOnc #OncSky #PallSky #SymptomScience
November 15, 2024 at 4:55 PM
@sarahlowry.bsky.social Welcome my friend. Glad to see you here. Where are all our incredible APP colleagues? #PallOnc #OncSky #PallSky #SymptomScience